Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

NCT02678572 ·Status: COMPLETED ·Phase: PHASE3

The Impact of Melanoma and Drug Treatment in the Real World

NCT03379454 ·Status: COMPLETED

A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma

NCT00001296 ·Status: COMPLETED ·Phase: PHASE3

Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases

NCT05903937 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma

NCT00062933 ·Status: COMPLETED ·Phase: PHASE2

Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment

NCT01920516 ·Status: UNKNOWN

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

NCT07276386 ·Status: RECRUITING ·Phase: PHASE2

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases

NCT04812470 ·Status: COMPLETED ·Phase: PHASE1

Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity

NCT00001577 ·Status: COMPLETED ·Phase: PHASE1

Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

NCT02094872 ·Status: COMPLETED ·Phase: PHASE2

Intratumoral Injection Of Alpha-Gal Glycosphingolipids

NCT00668512 ·Status: COMPLETED ·Phase: PHASE1

Intratumoral Application of L19IL2 in Patients With Malignant Melanoma

NCT01253096 ·Status: COMPLETED ·Phase: PHASE2

Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma

NCT03504696 ·Status: COMPLETED

Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma

NCT00002973 ·Status: COMPLETED ·Phase: PHASE2

Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases

NCT03754140 ·Status: WITHDRAWN ·Phase: PHASE2

Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma

NCT01213732 ·Status: COMPLETED ·Phase: PHASE1

A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma

NCT03696069 ·Status: COMPLETED

Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary

NCT02828202 ·Status: RECRUITING

PHP and Immunotherapy in Metastasized UM

NCT04283890 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma

NCT00707161 ·Status: TERMINATED ·Phase: PHASE2

A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma

NCT01986712 ·Status: COMPLETED

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

NCT02147951 ·Status: NO_LONGER_AVAILABLE

Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma

NCT01531244 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Efficacy of Chemotherapy Combined With Regional Hypothermia in Advanced Malignant Melanoma Patients With Progressive Soft Tissue Metastases

NCT00264056 ·Status: UNKNOWN ·Phase: NA

Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg

NCT00003789 ·Status: COMPLETED ·Phase: PHASE3